ALLO Earnings Results and History
Allogene Therapeutics, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.15 vs −$0.15 est −2.3%
- Revenue– vs $3K est
Filed ยท Press release
Key takeaways
from the press release- Net loss widened to $50.4 million from $41.4 million a year earlier, with no collaboration revenue in the quarter.
- Loss per share narrowed to $0.15 from $0.19, helped by a much larger share count of 346 million shares.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| Jun 2026 | $4.6M | – | −1011.2% | −$42.7M | −$0.13 | −$32.1M |
| Dec 2025 | $0 | – | – | −$38.8M | −$0.17 | −$27.6M |
| Sep 2025 | $0 | – | – | −$41.4M | −$0.19 | −$29.9M |
| Jun 2025 | $0 | – | – | −$50.9M | −$0.23 | −$39.1M |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Reports and price reactions
last 1 reportsYear by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $0 | −100.0% | – | −$190.9M | −$0.87 |
| Dec 31, 2024 | $22K | −76.8% | −1241813.6% | −$257.6M | −$1.32 |
| Dec 31, 2023 | $95K | −39.1% | −344986.3% | −$327.3M | −$2.09 |
| Dec 31, 2022 | $156K | −99.9% | −215087.2% | −$340.4M | −$2.38 |
| Dec 31, 2021 | $114.1M | – | −157.9% | −$182.1M | −$1.34 |
Filings and dates
SEC EDGAR- Nov 5, 2026Earnings release, Q3 20268-K Press release
- Nov 5, 2026Next earnings reportexpected
- Aug 12, 2026Quarterly report10-Q All filings
Also see ALLO institutional ownership and the earnings calendar.
ALLO earnings FAQ
What were ALLO's latest earnings?
For Q3 2026 Allogene Therapeutics, Inc. reported, GAAP EPS of -$0.15. The results were filed with the SEC on Nov 5, 2026.
When is ALLO's next earnings date?
Allogene Therapeutics, Inc. is expected to report on Nov 5, 2026. Dates can move until the company confirms them.
Is ALLO's revenue growing?
In the quarter ended Jun 30, 2026 revenue was $4.6M. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Allogene Therapeutics, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.